1. Arts EJ, Hazuda DJ (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2(4):a007161. doi: 10.1101/cshperspect.a007161
2. Kumari G, Singh RK (2013) Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment. Curr Pharm Des 19(10):1767–1783. doi: 10.2174/13816128113199990295
3. Burstein ME, Serbin AV, Khakhulina TV, Alymova IV, Stotskaya LL, et al (1999) Inhibition of HIV-1 replication by newly developed adamantane-containing polyanionic agents. Antivir Res 41(3):135–144. PMID: 10320046
4. Timofeyev DI, Perminova NG, Kiseleva YY, Nekludov VV, Vatolin GY, et al (2003) HIV-inhibiting activity of polyanionic matrixes and based on them substances containing adamantine and norbornane pharmacophores. Antibiot Chemother (Russia) 48(5):7–15. PMID: 12968467
5. Kiseleva YY, Perminova NG, Pliasunova OA, Timofeev DI, Serbin AV, et al (2005) Antiviral action of membranotropic compounds modified by adamantane and norbornene pharmacophores exerted on different HIV-1 strains. Mol Gen Mikrobiol Virusol (2):33–36. PMID: 15954475